The KEI written statement for the February 14, 2014 US International Trade Commission (USITC) hearing on India is attached here.
Among other things, the Statement includes 15 pages describing US compulsory licenses.
We also have a video play list with more than 9 hours of the Feb 12 and Feb 14 hearing.
http://www.youtube.com/playlist?list=PLLw9jWaZPEpwU_euETpPaVjdcFpKlCxp-
Continue Reading
Claire Cassedy did this interview at the KEI offices, following the February 24, 2014 USTR hearing on the Special 301.
Continue Reading
PhRMA’s submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests USTR classify India as a Priority Foreign Country citing the fact that India “continues to embrace these damaging policies, especially its IP rules, by publicly highlighting them… Continue Reading
The National Foreign Trade Council (NFTC) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India as a Priority Foreign Country and “conduct an out-of-cycle review of India to assess” Indian policies “across sectors,… Continue Reading
The National Association of Manufacturers’s (NAM) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requests that USTR designate India as a Priority Foreign Country citing concerns with India’s actions in multilateral fora including the UNFCCC, WTO and… Continue Reading
The Intellectual Property Owners Association’s (IPO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review expressed concern over various aspects of India’s policies including “India’s Forced Technology Transfer, Compulsory Licensing, and Lack of Effective IP Protection” and “Third… Continue Reading
The Biotechnology Industry Organization (BIO) submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to designate India a Priority Foreign Country. BIO expressed concerns over the robust use of patent oppositions in India: The Indian generic… Continue Reading
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
From GlaxoSmithKline’s 20-F report, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 3D: 6304 Compulsory licensing of patents: 42 3.D Risk factors Principal risk factors and uncertainties There are risks and uncertainties… Continue Reading